Seattle Genetics, Inc. (NASDAQ:SGEN) is now up 48.24% compared to a 12-month low of $50.71. We have seen the price to move 18.98% higher and get settled at $75.17 on 7/17/2019. At recent session, it appeared stuck in a range of $69 to $76.07. This company shares are 5.71% off its target price of $79.46 and the current market capitalization stands at $12.32B. The recent change has given its price a 10.68% lead over SMA 50 and -10.9% deficit over its 52-week high. The stock witnessed 4.97% gains, -1.99% declines and 4.39% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found SGEN’s volatility during a week at 4.59% and during a month it has been found around 3.8%.

Seattle Genetics, Inc. (SGEN) Top Holders

Institutional investors currently hold around $10.22 billion or 0% in SGEN stock. Look at its top three institutional owners: Baker Bros. Advisors Lp owns $3.23 billion in Seattle Genetics, Inc., which represents roughly 26.18% of the company’s market cap and approximately 31.56% of the institutional ownership. Similar statistics are true for the second largest owner, Wellington Management Group Llp, which owns 14,728,336 shares of the stock are valued at $930.54 million. The third largest holder is Primecap Management Co/Ca/, which currently holds $899.13 million worth of this stock and that ownership represents nearly 7.3% of its market capitalization.

Seattle Genetics, Inc. 13F Filings

At the end of March reporting period, 171 institutional holders increased their position in Seattle Genetics, Inc. (NASDAQ:SGEN) by some 4,471,249 shares, 116 decreased positions by 6,531,173 and 77 held positions by 150,748,450. That puts total institutional holdings at 161,750,872 shares, according to SEC filings. The stock grabbed 57 new institutional investments totaling 1,020,968 shares while 24 institutional investors sold out their entire positions totaling 1,046,136 shares.

Seattle Genetics, Inc. (NASDAQ:SGEN) Insider Trades

Multiple company employees have indulged in significant insider trading. Seattle Genetics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President and CEO SIEGALL CLAY B has sold 20,148 shares of Seattle Genetics, Inc. (SGEN) in the trading session dated Jul. 08, 2019. These shares are worth $1,347,700 and were traded at $66.89 each. The SEC filing shows that DANSEY ROGER D performed a sale of 5,416 shares. The Chief Medical Officer disposed these shares by way of transaction on Jun. 17, 2019. The company’s shares were given away at $68.6 per share worth to an income of some $371,538 to the account of DANSEY ROGER D.

President and CEO, SIEGALL CLAY B, sold 20,148 common shares of Seattle Genetics, Inc. (SGEN) in the open market. In a transaction dated Jun. 10, 2019, the shares were put up for sale at an average price of $69.05, raking in a sum of $1,391,219. After this sale, 746,294 common shares of SGEN are directly owned by the insider, with total stake valued at $56,098,920.

In the transaction dated May. 31, 2019, a great number of shares sold came courtesy the Chief Technical Officer; HIMES VAUGHN B disposed a total of 8,000 shares at an average price of $65.94, amounting to approximately $527,520. The insider now directly owns 177,329 shares worth $13,329,821.

Seattle Genetics, Inc. (SGEN) Analyst Guide

Several analysts have released their opinion on Seattle Genetics, Inc. (NASDAQ:SGEN), with 4 analysts believing it is a strong buy. Whereas 5 of them predict the stock is a hold. Also, there are 5 buy, 1 sell and 0 strong sell ratings, collectively assigning a 2.2 average brokerage recommendation [T1].